Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Abstract

Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).

Keywords

CrizotinibMedicineCeritinibLung cancerAlectinibAnaplastic lymphoma kinaseInternal medicineROS1OncologyChemotherapyHazard ratioDocetaxelChemotherapy regimenPemetrexedCancerSurgeryConfidence intervalAdenocarcinoma

MeSH Terms

AdultAgedAged80 and overAntineoplastic AgentsCarcinomaNon-Small-Cell LungCrizotinibDisease-Free SurvivalDocetaxelFemaleGlutamatesGuanineHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPemetrexedProtein Kinase InhibitorsPyrazolesPyridinesQuality of LifeTaxoidsYoung Adult

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Enriqueta Felip , Flávia De Angelis , Manuel Dómine +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

Pui San Tan , Gilberto Lopes , Sanchalika Acharyya +2 more

Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...

2015 European Journal of Cancer 17 citations

Publication Info

Year: 2013
Type: article
Volume: 368
Issue: 25
Pages: 2385-2394
Citations: 3353
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3353

OpenAlex

131

Influential

2829

CrossRef

Cite This

APA Style

                            
                                
                                    Alice T. Shaw, 
                                
                                    Dong‐Wan Kim, 
                                
                                    Kazuhiko Nakagawa
                                
                                et al.
                            
                            (2013). 
                            Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer. 
                            New England Journal of Medicine
                            , 368
                            (25)
                            , 2385-2394.
                            https://doi.org/10.1056/nejmoa1214886
                        

Identifiers

DOI: 10.1056/nejmoa1214886
PMID: 23724913

Data Quality

Data completeness: 86%